Treatment of egfr-dependent tumors by abin (a20 -binding inhibitor of nf kappab)
AssigneesVib Vzw, Universiteit Gent, Vrije Universiteit Brussel
InventorsRudi Beyaert, Hilde Revets, Lieven Huang
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment of epidermal growth factor-family receptor- (ErbB-) dependent tumors. More specifically, the present invention relates to the use of ABIN for the preparation of a medicament to inhibit epidermal growth factor- (EGF-) induced proliferation, and to treat ErbB-dependent tumors.
Claims19
-8. (canceled)
A method of treating a tumor cell overexpressing ErbB, the method comprising delivering ABIN to said tumor cell.
A method of blocking EGF-EGFR-dependent cell proliferation in a cell, the method comprising:
- delivering ABIN to said cell and blocking EGF-EGFR-dependent cell proliferation in said cell.
A method of inhibiting ErbB-dependent NF-κB activation in a cell, the method comprising:
- delivering ABIN to said cell and inhibiting ErbB-dependent NF-κB activation in said cell.
Dependencies are inferred from the claim text.